Blood Cell Count Ratios at Baseline are Associated with Initial
Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Na ïve,
Schizophrenia-Spectrum Disorder
Conclusion Our study emphasizes the potential clinical significance of
baseline NLR and MLR levels as predictors of initial clozapine treatment
response in patients with TRS. Future studies with larger sample sizes and
longer follow-up periods should replicate our findings. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text (Source: Pharmacopsychiatry)
Source: Pharmacopsychiatry - April 15, 2024 Category: Psychiatry Authors: Llorca-Bof Ã, Vicent Bioque, Miquel Madero, Santiago Mallorqu Ã, Andrea Oliveira, Cristina Garriga, Marina Parellada, Eduard Garc Ãa-Rizo, Clemente Tags: Original Paper Source Type: research
Comparable Psychotropic Prescription Rates After Hospital Discharge
Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory
Infection
Discussion The development of psychiatric symptoms should be closely
observed, especially in patients who experienced increased severity during
hospitalization, regardless of whether they suffered from COVID-19. [...] Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text (Source: Pharmacopsychiatry)
Source: Pharmacopsychiatry - March 26, 2024 Category: Psychiatry Authors: Takahashi, Yuna Yatomi, Taisuke Yamaguchi, Naohito Yoshimura, Kimio Hori, Satoko Uchida, Hiroyuki Tags: Original Paper Source Type: research
Medicinal Use of Different Cannabis Strains: Results from a Large
Prospective Survey in Germany
Conclusions Patients self-reported very good efficacy and tolerability of
MC. There was no evidence suggesting that specific MC strains are superior
depending on the disease to be treated. [...] Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text (Source: Pharmacopsychiatry)
Source: Pharmacopsychiatry - March 12, 2024 Category: Psychiatry Authors: Szejko, Natalia Becher, Eva Heimann, Florian Grotenhermen, Franjo M üller-Vahl, Kirsten R. Tags: Original Paper Source Type: research
Risperidone-Induced Leukoneutropenia: Evidence from a Positive
Rechallenge and Review of the Literature
Pharmacopsychiatry 2024; 57: 78-81 DOI: 10.1055/a-2262-8297Antipsychotics can cause hematologic disorders, and they can have life-threatening
consequences. Risperidone, less commonly associated with hematologic adverse
effects, is an atypical antipsychotic medication used to treat conditions such as
schizophrenia, bipolar disorder and irritability associated with autism. While
risperidone primarily affects the central nervous system, it can have some
hematologic adverse effects, although these are relatively rare. It is crucial to
note that these side effects are not common, and most people taking r...
Source: Pharmacopsychiatry - March 12, 2024 Category: Psychiatry Authors: Sahnoun, Dhouha Ghanmi, Ahlem Gazzeh, Soumaya Saguem, Bochra Slim, Raoudha Nakhli, Jaafar Ben Salem, Chaker Tags: Letter to the Editor Source Type: research
Implications of Online Self-Diagnosis in Psychiatry
Pharmacopsychiatry 2024; 57: 45-52 DOI: 10.1055/a-2268-5441Online self-diagnosis of psychiatric disorders by the general public is
increasing. The reasons for the increase include the expansion of Internet
technologies and the use of social media, the rapid growth of direct-to-consumer
e-commerce in healthcare, and the increased emphasis on patient involvement in
decision making. The publicity given to artificial intelligence (AI) has also
contributed to the increased use of online screening tools by the general
public. This paper aims to review factors contributi...
Source: Pharmacopsychiatry - March 12, 2024 Category: Psychiatry Authors: Monteith, Scott Glenn, Tasha Geddes, John R. Whybrow, Peter C. Achtyes, Eric D. Bauer, Michael Tags: Review Source Type: research
---
Pharmacopsychiatry 2024; 02 Article in Thieme eJournals: Table of contents  |  Congress (Source: Pharmacopsychiatry)
Source: Pharmacopsychiatry - March 12, 2024 Category: Psychiatry Source Type: research
Perceptions, Experiences, and Patterns of Cannabis Use in Individuals
with Mood and Anxiety Disorders in the Context of Cannabis Legalization and
Medical Cannabis Program in Canada – A Qualitative Study
This study aims to understand motivations, perceptions,
effects, and patterns of CU in individuals with mood and anxiety disorders.
Methods Thirty-six adult patients diagnosed with mood or anxiety
disorders, obsessive-compulsive disorder, or posttraumatic stress disorder who
were currently using cannabis completed an in-depth qualitative interview on
individual motivations, perceptions, experiences, effects, and patterns of their
CU. The thematic analysis focused on phases of CU and sources of cannabis
products and information.
Results Reported motivatio...
Source: Pharmacopsychiatry - March 11, 2024 Category: Psychiatry Authors: Das, Ankita Hendershot, Christian S. Husain, M.Ishrat Knyahnytska, Yuliya Elsaid, Sonja Le Foll, Bernard Kloiber, Stefan Tags: Original Paper Source Type: research
Cannabinoids for Behavioral Symptoms in Dementia: An
Overview
Pharmacopsychiatry DOI: 10.1055/a-2262-7837Dementia, with loss of memory, cognitive abilities, and independent daily
functioning, is increasing worldwide, related to an aging population. Currently,
there is no curative treatment for dementia. Treatment of the frequently
occurring behavioral and psychological symptoms of dementia (BPSD) is partially
effective and associated with significant side effects. Cannabinoids are lipophilic molecules acting on the CB1 end CB2 receptors,
essential for main biological processes such as sleep, appetite, memory, and
pain. Canna...
Source: Pharmacopsychiatry - March 6, 2024 Category: Psychiatry Authors: Broers, Barbara Bianchi, Federica Tags: Review Source Type: research
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical
Approach and Overview of the Literature
Pharmacopsychiatry DOI: 10.1055/a-2256-0098Although an increasing number of patients suffering from mental illnesses
self-medicate with cannabis, current knowledge about the efficacy and
safety of cannabis-based medicine in psychiatry is still extremely
limited. So far, no cannabis-based finished product has been approved for
the treatment of a mental illness. There is increasing evidence that
cannabinoids may improve symptoms in autism spectrum disorder (ASD), Tourette
syndrome (TS), anxiety disorders, and post-traumatic stress disorder (PTSD).
Accordin...
Source: Pharmacopsychiatry - March 1, 2024 Category: Psychiatry Authors: M üller-Vahl, Kirsten R. Tags: Review Source Type: research
Unraveling the Influence of Age, IQ, Education, and Negative Symptoms
on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree
Analysis
Conclusions These findings emphasize the multifaceted nature of
neurocognitive functioning in patients with schizophrenia, with the
PANSS-negative score being an important predictor. This gives rise to a role in
addressing negative symptoms as a therapeutic objective for enhancing cognitive
impairments in these patients. Further research must examine nonlinear
relationships among various moderating factors identified in this work,
especially the role of D2 occupancy. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJourna...
Source: Pharmacopsychiatry - February 22, 2024 Category: Psychiatry Authors: Hart, Xenia M. Mitsukura, Yasue Bies, Robert R. Uchida, Hiroyuki Tags: Pharmacopsychiatry Women Source Type: research
The Relevance of Integrating CYP2C19 Phenoconversion Effects into
Clinical Pharmacogenetics
Discussion PC of CYP2C19 changes phenotypes but does not improve
correlations with serum concentrations. However, only a limited number of
patients received perturbators of CYP2C19. Studies with large numbers of
patients are still lacking, and thus, it cannot be decided if there are minor
differences and which method of correction to use. For the time being, PC is
relevant in individual patients treated with CYP2C19-affecting drugs, for
example, esomeprazole. To ensure adequate serum concentrations in these
patients, this study suggests the use of therap...
Source: Pharmacopsychiatry - February 14, 2024 Category: Psychiatry Authors: Scherf-Clavel, Maike Weber, Heike Unterecker, Stefan Frantz, Amelie Eckert, Andreas Reif, Andreas Deckert, J ürgen Hahn, Martina Tags: Original Paper Source Type: research
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Pharmacopsychiatry DOI: 10.1055/a-2228-6118The endocannabinoid system shows promise as a novel target for treating
psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid,
has been investigated in several psychiatric conditions, with diverse effects
and an excellent safety profile compared to standard treatments. Even though the
body of evidence from randomised clinical trials is growing, it remains
relatively limited in most indications. This review comprises a comprehensive
literature search to identify clinical studies on the effects of CBD...
Source: Pharmacopsychiatry - January 24, 2024 Category: Psychiatry Authors: Dammann, Inga Rohleder, Cathrin Leweke, F. Markus Tags: Review Source Type: research
Effectiveness of Medical Cannabis for the Treatment of Depression: A
Naturalistic Outpatient Study
Conclusions Medical cannabis was well tolerated and dropout rate was
comparable to those in clinical trials of antidepressant medication. Patients
reported a clinically significant reduction of depression severity. Further
research on the effectiveness of medical cannabis for MDD seems warranted. Risks
of this medication, such as sustaining or inducing a cannabis use disorder, or
side effects such as poor concentration, must be taken into consideration. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents Â...
Source: Pharmacopsychiatry - January 11, 2024 Category: Psychiatry Authors: Specka, Michael Bonnet, Udo Schmidberg, Lisa Wichmann, Julian Keller, Martin Scholze, Christian Scherbaum, Norbert Tags: Original Paper Source Type: research
Overview: Chronic Pain and Cannabis-Based Medicines
Pharmacopsychiatry DOI: 10.1055/a-2231-6630Chronic pain is primarily conceptualized as a disease in its own right when it is
associated with emotional distress and functional impairment.
Pathophysiologically, dysfunction of the cortico-mesolimbic connectome is of
major importance, with overlapping signals in the nociceptive and stress
systems. The endocannabinoid system plays an important role in the central
processing of nociceptive signals and regulates the central stress response.
Clinically, there is moderate evidence that cannabis-based medicines (CBM) can
...
Source: Pharmacopsychiatry - January 10, 2024 Category: Psychiatry Authors: Karst, Matthias Tags: Review Source Type: research
Patient Perspectives on Pharmacotherapy of Alcohol
Dependence
The objective of
the present study was to identify from patients’ perspective factors
that prevent the initiation and compliance with pharmacological treatment of
AD.
Methods Patients from inpatient alcohol withdrawal treatment underwent a
standardized interview. Questions included socio-demographic data, history of
AD, treatment history, knowledge and personal experience regarding
pharmacotherapy of AD, and personal views about the causes of AD.
Results Three hundred patients (mean age 47.3 years, 27.7% female,
mean duration of AD 8.9 years,...
Source: Pharmacopsychiatry - December 5, 2023 Category: Psychiatry Authors: Wellensiek, Julian Specka, Michael Just, Johannes Banger, Markus Bonnet, Udo Scherbaum, Norbert Tags: Original Paper Source Type: research
